Objective This guideline will provide the practicing endocrinologist with an approach to the
assessment and treatment of dyslipidemia in patients with endocrine diseases, with the …

METHODS This CPG was developed in accordance with the AACE Protocol for
Standardized Production of Clinical Practice Guidelines—2010 Update (

Objective The development of these guidelines is mandated by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology …

The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical
activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders …

Objective: The aim was to develop clinical practice guidelines on hypertriglyceridemia.
Participants: The Task Force included a chair selected by The Endocrine Society Clinical …

Objective: The objective was to develop clinical practice guidelines for the primary
prevention of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) in patients …

Cardiovascular disease is more prevalent in type 1 and type 2 diabetes, and continues to be
the leading cause of death among adults with diabetes. Although atherosclerotic vascular …

Recently, considerable progress has been made in understanding the genetic basis of
dyslipidemias and in studying the safety and efficacy of lipid-lowering drugs for coronary …

Abstract Purpose of Review Hypertriglyceridemia (HTG) is common and is a significant
contributor to atherosclerosis and pancreatitis risk. Specific HTG treatments have had …

A severe elevation in triglycerides (TG;≥ 500 mg/dL) increases the risk for pancreatitis. TG
levels≥ 200 mg/dL are associated with a greater risk of atherosclerotic coronary heart …